-
Jan 16, 2025 | 
ophthalmologytimes.com | Sydney Crago
City Therapeutics, Inc. is set to collaborate with Bausch + Lomb on the development of a novel therapy for the treatment of retinal diseases including geographic atrophy (GA). The arrangement of this agreement states that City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.
-
Jan 13, 2025 | 
ophthalmologytimes.com | Sydney Crago
With the start of 2025, many companies have evaluated the skills and depth of their team as they prepare for the advances and changes that are to come. This has led to the appointment of several new executives in the pharmaceutical industry. The following updates are listed in alphabetical order by company and not a comprehensive list of announcements. EyePoint has added Reginald J. Sanders, MD, FASRS, to its Board of Directors.
-
Jan 8, 2025 | 
ophthalmologytimes.com | Sydney Crago
With the busy holiday season and the winter weather hitting much of the United States in the first few days of 2025, there have been many things on the minds of our readers that may not have been ophthalmology related. That’s why we are here to catch you up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding that you may have missed.
-
Jan 7, 2025 | 
optometrytimes.com | Sydney Crago |Modern Retina
The Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial convened and approved continuation of the second phase of the Phase 1/2 study. The candidate being evaluated, OCU410 (AAV5-hRORA), is a novel modifier gene therapy candidate being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
-
Dec 11, 2024 | 
ophthalmologytimes.com | Sydney Crago
Exegenesis Bio provided an update on the company’s treatment candidates for wet age-related macular degeneration (wet AMD). EXG102 is an investigational gene therapy for wet AMD that is administered by subretinal injection. EXG202, a next generation version, incorporates the same genetic cargo as EXG102, but is delivered to deep retinal cells by a highly-specific ocular capsid that enables administration by intravitreal injection, a less invasive, non-surgical approach.
-
Dec 10, 2024 | 
ophthalmologytimes.com | Sydney Crago |Martin Harp |Sheryl Stevenson |David Hutton
CommentaryVideoDecember 10, 2024Author(s):,In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers. In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers. Editor's note: The below transcript has been lightly edited for clarity.
-
Dec 8, 2024 | 
ophthalmologytimes.com | Sydney Crago |Martin Harp |Sheryl Stevenson |David Hutton
In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers. Editor's note: The below transcript has been lightly edited for clarity. So I think one thing is to remember to have a high index of suspicion for thyroid eye disease. Thyroid eye disease is the most common cause of either unilateral or bilateral proptosis in adults.
-
Dec 4, 2024 | 
ophthalmologytimes.com | Sydney Crago
NewsArticleDecember 4, 2024SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug Administration (FDA). More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The trial is expected to close randomization in early December 2024.
-
Dec 4, 2024 | 
ophthalmologytimes.com | Sydney Crago |Martin Harp |David Hutton |Sheryl Stevenson
CommentaryVideoDecember 4, 2024Author(s):,In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers. In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers. Editor's note: The below transcript has been lightly edited for clarity.
-
Oct 27, 2024 | 
ophthalmologytimes.com | Sheryl Stevenson |David Hutton |Sydney Crago |Grace Koennecke
John Josephson, MD, from the Eye Specialists and Surgeons of Northern Virginia, shared insights on office-based surgeries and how it allows for the addition of new technologies and new procedures at this year's AAO meeting held in Chicago, Illinois. Editor's note: The below transcript has been lightly edited for clarity. Hi. My name is John Josephson from Eye Specialists and Surgeons of Northern Virginia. We're in Fairfax.
